MLX and osteosarcoma: COX-2 dependent pathways of MLX anticancer activity involve prostaglandin E2 (PGE2) production inhibition which can be effective in cancers with high COX-2 expression such as osteosarcoma or hepatocellular carcinoma [23,24].